Print the page
Increase font size
Groundhog Day (Lockdown Edition)

Groundhog Day (Lockdown Edition)

Chris Campbell

Posted August 23, 2023

Chris Campbell

Alex Jones.

The name alone is enough to spark heated debates in homes and social circles across the nation.

It’s synonymous with conspiracy theories, fiery rhetoric, and a style of journalism that is unashamedly provocative.

When Jones speaks, people either seethe… or cheer… or run away… or tiptoe closer with feigned disinterest.

As usual, Jones has stirred the pot yet again…

Igniting a flurry of speculation on Musk's former bird app, X.

And… what if he’s right?

(Broken clocks. Blind squirrels. And all that.)

The Informant!

In case you missed it: 

According to Jones, a “high-level manager in the TSA,” risking much to break rank and step into the light, has confided in him.

The word from the informant? By the time the leaves turn and October graces us, travelers might find themselves once again ensnared in the tangled weave of face masks.

And…

As winter's icy grip approaches, and December takes hold, there may be a return to the all-too-familiar dance of restrictions and lockdowns.

Normally, we’d shrug it off. Claims of “secret whistleblowers” are a dime-a-dozen online.

But, the thing…

The media is indeed ramping up the rhetoric on lockdowns, booster shots, and masks.

To wit:

CNN Tweet

No less, major Hollywood studio Lionsgate… George Morris Brown College… Rutgers University… and more have already announced fresh new mandates.

What if we are in for another round of lockdowns?

Who stands to benefit? What are the paranoids doing to prepare?

And what’s the one “variant-proof” investment that should do well either way?

The Groundhog Day Portfolio

Let’s take a trip down memory lane.

As lockdowns halted travel, astute investors eyed put options on major oil companies, foreseeing a decline in oil demand.

Meanwhile, the heightened demand for personal protective equipment due to lockdowns increased the allure of stocks from key PPE manufacturers.

The global urgency for vaccination thrust pharmaceutical giants into the limelight, particularly as new COVID-19 variants emerged.

The year also marked a pivotal shift towards remote work and telehealth, with companies like Teladoc Health and Zoom becoming integral to this new normal.

But one investment on the “covid 2.0 watchlist” stands out.

By many accounts, it could be poised to succeed regardless.

It’s natural gas.

Extended winter lockdowns boosted the need for heating, favoring investments in natural gas entities. But a cold snap would do that regardless.

Also, since a lot of natural gas travels through the Panama Canal -- which is, of course, experiencing a drought -- that could also push prices up, too.

Should you believe the hype? That’s up to you.

But the point is to win no matter what.

Tokenized GDP: Signal or Spectacle?

Posted August 29, 2025

By Chris Campbell

Call it survival, call it control, call it surrender—call it whatever you want. But also call it the future.

Silver, Uranium, Lithium... Oh, My!

Posted August 28, 2025

By Chris Campbell

Silver is about to see the same catalyst that sent uranium and lithium into the stratosphere. But this time, it'll be even more violent.

The Bitcoin Heating Dividend (American Edition)

Posted August 27, 2025

By Chris Campbell

Waste only exists because we haven’t figured out how to harvest its value.

Why I Said College Was a Scam (and Still Do)

Posted August 26, 2025

By James Altucher

The first time I wrote “college is worthless,” I got death threats—now it’s just common sense.

The Scar Tissue Cycle (Crypto)

Posted August 25, 2025

By Chris Campbell

Crypto has always been about cycles. Retail, hedge funds, VCs, then institutions. But this cycle is different.

The $26T Crypto Takeover

Posted August 22, 2025

By Chris Campbell

It’s not just Bitcoin at $500k or Ethereum at thirty thousand. It’s crypto absorbing a chunk of the entire financial stack.